Hair Loss on Zepbound (Tirzepatide): Incidence, Severity, and Realistic Expectations

Print or save as PDF

See the public record for Tirzepatide

How common is hair loss on Zepbound?

The most reliable numbers are in the Zepbound label. They come from a pool of two placebo-controlled weight-management trials, SURMOUNT-1 and SURMOUNT-2, that ran up to 72 weeks in adults with obesity or overweight, with or without type 2 diabetes: 958 patients on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg [1].

Hair loss was reported by 1% of the placebo group, 5% of the 5 mg group, 4% of the 10 mg group and 5% of the 15 mg group [1]. It appears in the label's table of adverse reactions that occurred in at least 2% of patients and more often than with placebo, and it is also named among the most common reactions overall [1].

One detail is worth noting: there is no clean dose gradient. The 10 mg group reported less hair loss than the 5 mg group, and 5 mg and 15 mg came out the same [1]. These figures are counts of reported adverse events from trial safety tables, not measurements of hair density or shedding counts.

For context, a 2026 systematic review of 24 studies found that semaglutide and tirzepatide had the highest reported hair loss rates among GLP-1 receptor agonists [3]. A separate review of skin-related reports to the FDA Adverse Event Reporting System found alopecia among the five most common cutaneous reactions across this drug class, and found significantly higher alopecia reporting when these drugs were used for type 2 diabetes than for weight management (P<0.001) [5].

Who reports it, and why women far more than men

The sex difference in the Zepbound label is large. Hair loss was reported by 7.1% of women and 0.5% of men taking Zepbound, and by 1.3% of women and 0% of men on placebo [1]. The same label states that the hair loss was associated with weight reduction [1].

Weight loss on this drug is substantial. In SURMOUNT-1, mean weight change at 72 weeks was -15.0% on 5 mg, -19.5% on 10 mg and -20.9% on 15 mg, versus -3.1% on placebo, in 2,539 adults with obesity or overweight and no diabetes [2]. A 2026 systematic review concluded that rapid weight loss is a potential contributor to hair loss with these drugs, particularly the telogen effluvium pattern, and that causality has not been established [3]. The same review found women disproportionately affected [3].

A cross-sectional questionnaire study of 254 GLP-1 receptor agonist users in Saudi Arabia found no significant difference in hair-loss prevalence between products (p=0.116), but severe hair loss was significantly more common among Mounjaro (43.4%) and Saxenda (42.9%) users than the other groups (p<0.001), and men were less likely to report hair loss than women (adjusted odds ratio 0.36) [6]. That is a single-country, self-reported survey, so treat the percentages as a signal rather than a rate you can apply to yourself.

Is it telogen effluvium?

Telogen effluvium is a nonscarring, diffuse shedding from the scalp that appears around 3 months after a triggering event. It is usually self-limiting, lasts about 6 months, and typically causes loss of less than 50% of scalp hair [4].

The hair-loss subtype was often not classified in the underlying reports, but where a subtype was assigned, androgenetic alopecia and telogen effluvium were the predominant ones, and tirzepatide was most frequently linked to telogen effluvium [3].

How long does it last?

For telogen effluvium generally, shedding starts about 3 months after the trigger and the episode usually resolves on its own over roughly 6 months [4]. Neither the Zepbound label nor the pooled trial reports give a timeline for how long hair loss lasts on this drug or when regrowth occurs [1].

How severe is it, and does anyone stop treatment?

The label records no Zepbound patient discontinuing treatment because of hair loss; one placebo patient did [1]. For comparison, discontinuation for any adverse reaction was 4.8% on 5 mg, 6.3% on 10 mg and 6.7% on 15 mg, versus 3.4% on placebo, mostly for gastrointestinal effects in the first few months [1].

A review of telogen effluvium notes that increased shedding does not by itself show a cause [4].

Do nutrition and supplements help?

Sudden weight loss and reduced protein intake are well-known triggers of acute telogen effluvium [7]. The review says laboratory testing may be warranted where a dietary history or exam suggests a deficiency, and that a documented deficiency should be corrected [7]. Whether supplements help someone who is not deficient is unresolved, and some supplements carry the risk of worsening hair loss or causing toxicity [7].